Hansa Biopharma to Participate in Kidney Disease Summit
Hansa Biopharma announced its participation in the Wedbush PacGrow Renal Summit. COO Maria Törnsén will join a discussion on kidney transplantation challenges.
Lund, Sweden – Hansa Biopharma AB, a biopharmaceutical company, announced its participation in the Wedbush PacGrow Renal Summit on July 3, 2026. The summit focuses on advancements and challenges in kidney disease and transplantation.
Maria Törnsén, Chief Operating Officer and President of U.S. Operations for Hansa Biopharma, is scheduled to participate in a fireside chat titled "Don't Be So Sensitive - Bringing Kidneys to the Over-Sensitized." This session will address the complexities of kidney transplantation for patients with high levels of antibodies, which can lead to organ rejection.
Hansa Biopharma is developing and commercializing enzyme-based therapies aimed at modifying the immune system. Their approach seeks to enable organ transplants for highly sensitized patients who often face limited viable options. The company's technology targets specific antibodies involved in the rejection process.
The company's presence at the summit underscores its commitment to addressing unmet needs in nephrology and organ transplantation. Hansa Biopharma's participation provides a platform to discuss potential solutions and advancements in the field.